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Chemotherapy agents are notorious for producing severe side-effects. One approach to
mitigating this off-target damage is to deliver the chemotherapy directly to a tumor via
transarterial infusion, or similar procedures, and then sequestering any chemotherapeutic in
the veins draining the target organ before it enters the systemic circulation. Materials capable
of such drug capture are yet to be fully realized. Here, we report the covalent attachment of
genomic DNA to iron-oxide nanoparticles. With these magnetic materials, we captured three
common chemotherapy agents—doxorubicin, cisplatin, and epirubicin—from biological
solutions. We achieved 98% capture of doxorubicin from human serum in 10min. We further
demonstrate that DNA-coated particles can rescue cultured cardiac myoblasts from lethal
levels of doxorubicin. Finally, the in vivo efﬁcacy of these materials was demonstrated in a
porcine model. The efﬁcacy of these materials demonstrates the viability of genomic DNA-
coated materials as substrates for drug capture applications.
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The systemic toxicity of chemotherapy is a widely recog-nized problem in oncology. Off-target damage often per-sists indeﬁnitely, adversely affects patient survival, and
restricts dose and treatment options1,2. Direct administration of
chemotherapy agents to the tumor via transarterial che-
moembolization (TACE), or similar procedures, followed by
sequestration of any chemotherapeutic that enters systemic cir-
culation would mitigate this damage if materials capable of such
drug capture were fully realized3,4.
Hepatocellular carcinoma (HCC) is the third leading cause of
cancer-related deaths worldwide5. Liver transplantation is the
most deﬁnitive approach for treatment; however, less than 30% of
HCC patients are eligible6. Direct delivery of drug to a tumor via
intraarterial chemotherapy (IAC) and its variant, TACE, is often
used as a bridge to transplantation, shrinking HCC or at least
controlling its growth through recurrent treatments until curative
transplant is possible. In cases where surgery is untenable, che-
motherapy is often the only recourse. Targeted therapy, however,
does not completely eliminate side-effects.
Three of the most common drugs used to treat HCC are
doxorubicin (DOX), epirubicin (EPI), and cisplatin (Fig. 1c), all
of which act on DNA7. DOX and EPI function by intercalating
between DNA base pairs, while cisplatin is a DNA crosslinker
that functions by binding to guanine8,9. A major problem for
these anticancer compounds is toxicity in non-targeted tissues.
DOX and EPI toxicity can result in cardiomyopathy and con-
gestive heart failure8–10. Similarly, cisplatin elicits side-effects
including extensive nephrotoxicity and neurotoxicity11,12. To
reduce the likelihood of cardiac toxicity, cumulative dosage of
DOX is generally limited by clinicians to 400–450 mg/m2, though
lower cumulative dosages (300 mg/m2) are known to increase the
risk of congestive heart failure13,14. Still, a single standard dose of
DOX (50–75 mg) can result in severe side-effects, yet higher
dosages of DOX are known to be associated with greater tumor
suppression. Consequently, a balance must be struck in order to
maximize drug dose, leading to better tumor suppression, while
simultaneously avoiding catastrophic off-target toxicity. Although
limiting a patient’s lifetime cumulative dose is the most effective
way to avoid cardiotoxicity, this approach necessarily limits anti-
cancer efﬁcacy15.
The unwanted systemic toxicity of chemotherapy agents has
inspired a number of more targeted approaches. One such
approach is TACE, during which liver blood ﬂow is occluded in
conjunction with administration of high dose chemotherapy
directly to the tumor3,16. Both during TACE and after liver blood
ﬂow is restored, however, up to 50% of residual chemother-
apeutics enter systemic circulation and cause off-target toxicity17.
Efforts have been made toward reducing non-targeted toxicity
during TACE. In 2014 Patel and coworkers proposed che-
motherapy ﬁltration devices (“ChemoFilters”) that employed
sulfonated ion-exchange resins with afﬁnity for DOX. Such a
device could be deployed via catheter in the hepatic vein,
“downstream” from the site of chemotherapy administration,
where it can intercept any residual chemotherapy agents before
they reach the heart and enter systemic circulation. They
demonstrated a 52% reduction in DOX concentration from
porcine serum over 10 min, and showed that such a device could
be successfully deployed during a simulated TACE procedure3. In
2016, the ChemoFilter approach inspired the development of
more elaborate block copolymer membranes for DOX capture,
which achieved up to 90% removal of DOX in 31 min from
phosphate buffered saline (PBS)4.
A ChemoFilter device is intended to be placed downstream of
blood outﬂow from the tumor that is being treated with intra-
arterial chemotherapeutics. In the case of HCC, which is located
in the liver, the ChemoFilter would be placed into the suprahe-
patic inferior vena cava (IVC) immediately prior to administra-
tion of IAC into the hepatic artery and then removed shortly after
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drug capture has been achieved3,18. Here we report the devel-
opment of a drug-capture material based on genomic DNA and
iron oxide particles. In vitro studies conﬁrm that these materials
can rescue cells from the toxic effects of DOX. A ChemoFilter
device is constructed from this material that rapidly removes
chemotherapy agents from relevant biological solutions, including
human serum and porcine blood, and in vivo studies conﬁrm that
DOX can be removed from the bloodstream by an intraarterial
device constructed from these iron oxide/genomic DNA
materials.
Results and discussion
Material design and synthesis. Inspired by the ChemoFilter
concept, we designed and synthesized DNA-functionalized
materials based on magnetite (Fe3O4) nanoparticles, capable of
rapidly capturing chemotherapy agents. Central to our approach
is the direct covalent attachment of genomic DNA. Functiona-
lizing surfaces with DNA has historically involved tagging either
the backbone or bases of synthetic DNA with an appropriate
moiety, or attaching the DNA via a reactive end-group. These
approaches are highly useful and enable complete control of the
DNA sequence used resulting in the development of numerous
interesting materials19–26; however, they are limited by the rela-
tively high cost of synthetic DNA. The synthesis of large amounts
of such materials would be prohibitively expensive for most
applications.
Functionalization with genomic DNA is an alternative
approach that may be appropriate for certain applications;
however, this approach is relatively unexplored. Pierre and
coworkers recently synthesized magnetic nanoparticles with
surface-bound intercalating groups, and showed that such
materials can bind to genomic DNA27. To our knowledge,
however, no one has reported the covalent attachment of genomic
DNA to a surface. Here, we report two methods of attaching
genomic DNA to nanoparticles, both on multi-gram scale
(Fig. 1a). We show that the resulting materials are capable of
removing DNA-targeting chemotherapy agents from solution
both rapidly and in the presence of potential biological
intereferents (e.g., serum proteins and other blood components).
DNA-alkylating agents are a common motif in chemotherapy.
By forming covalent crosslinks between DNA strands, these drugs
prevent the DNA from being accurately duplicated, ultimately
leading to apoptosis. To attach genomic DNA to magnetic
nanoparticles, we used an approach analogous to DNA-alkylat-
ing/crosslinking drugs (Fig. 1a). The ﬁrst approach was inspired
by cisplatin. To synthesize IONP-Pt-DNA samples, the
hydroxylated surface of Fe3O4 was silylated with N-(2-ami-
noethyl)-3-aminopropyltrimethoxysilane exposing a chelating
diamine functionality. This sample was treated with an excess
of potassium tetrachloroplatinate to create an analog of cisplatin
by which DNA could be anchored to the surface. Cisplatin’s
cytotoxicity is thought to stem from its coordination with
nucleophilic N7-sites of purine bases, resulting in crosslinks28.
We hoped to accomplish DNA crosslinking to the surface
through this mechanism. The sample was then exposed to DNA
to produce IONP-Pt-DNA.
The second approach was modeled on nitrogen mustard
chemotherapy agents. IONP-HN3-DNA samples were prepared
ﬁrst by functionalizing Fe3O4 with 4-aminobutyltriethoxysilane to
install free amines on the surface. This particle was then treated
with excess tris(2-chloroethyl)amine hydrochloride (HN3·HCl) to
create a scaffold for DNA functionalization. HN3·HCl, the
hydrochloride salt of the nitrogen mustard HN3, undergoes
aziridinium formation when deprotonated, and is attacked readily
by the nucleophilic moieties of DNA29. The functionalized
particle was exposed to DNA resulting in IONP-HN3-DNA. Both
materials were characterized by scanning electron microscopy,
electron dispersive scattering (EDS), elemental analysis, and
infrared spectroscopy (see Supplementary Figs. 2& 3 and 11–24,
and Supplementary Table 1). Microscopy images of the particles
in solution revealed signiﬁcant aggregation resulting in an average
particle diameter of 4.2 μm with several larger (>10 μm)
aggregates. Elemental analysis indicated that these aggregates
were 18% DNA by mass in the case of IONP-HN3-DNA and
14.7% DNA by mass in the case of IONP-Pt-DNA.
In vitro testing in simple solutions, serum, and blood. In order
to evaluate the efﬁcacy of our materials at scavenging che-
motherapy agents from solution we studied DOX-binding in PBS
and human serum at 37 °C to approximate the biological envir-
onment in which these materials would have to operate (Fig. 1b).
We found that IONP-HN3-DNA was able to capture 93% of
DOX, on average, from a 0.05 mg/mL solution of human serum
in 25min, while IONP-Pt-DNA averaged 79% (Fig. 2a). In both
cases, the kinetics were extremely rapid, with about 50% of DOX
capture occurring within 1 min in the case of IONP-Pt-DNA and
over 65% DOX capture occurring within 1 min for IONP-HN3-
DNA. Based on these results, we carried out all further tests with
IONP-HN3-DNA.
Interestingly, both materials were highly effective, despite the
known binding of DOX with serum albumin. It is known that
DNA intercalation is the kinetically more favorable process30,31,
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Fig. 2 DOX capture in human serum and porcine blood. a Decrease in DOX concentration in human serum, determined by ﬂuorescence, as a result of DOX
capture by IONP-HN3-DNA and IONP-Pt-DNA; 100 ± 5mg particle in 20mL (0.05mg/mL), 1 mg total DOX, 37 °C; error bars= 1 standard deviation (n=
3). b Decrease in DOX plasma concentration as a result of DOX capture by IONP-HN3-DNA from porcine whole blood; 100 ± 5mg IONP-HN3-DNA in
20mL (0.05mg/mL), 1 mg total DOX, 37 °C; error bars= 1 standard deviation (n= 3)
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and we believe that this kinetic advantage enabled our material to
capture DOX from serum solution, despite the thermodynamics
being in favor of serum binding overall. We posit that over longer
timescales, serum binding would be the dominant process;
however, since TACE is a relatively short procedure (<1 h), we
believe that kinetic factors will dominate in the performance of
any material or device.
Drug capture was also evaluated in porcine whole blood, by
measuring DOX plasma concentration over time. We observed
some DOX removal due to binding to the non-plasma blood
components, which we cannot deconvolute from capture by our
materials. Nevertheless, there is rapid reduction of DOX
concentration in the blood plasma within 1 min after exposure
to our material, reaching a 92% reduction in DOX plasma
concentration over 10 min, in stark contrast to the control
experiment (Fig. 2b). This experiment conclusively demonstrates
that our materials are capable of capturing DOX from whole
blood.
To better understand the DOX-capture capacity of IONP-
HN3-DNA, we performed a series of experiments in which
nanoparticle loading was systematically varied (Fig. 3a, b, further
data in the Supplementary Information). These experiments
revealed a roughly linear trend in DOX-capture as a function of
the amount of particle added, up to a plateau around 100mg
material added per mg DOX, resulting in ~90% DOX capture in
10 min. Further DOX capture appears less favorable after this
point. We believe this plateau is the result of competition with
serum binding, which makes that portion of DOX unavailable for
capture by our particles, as well as the typical kinetic effects of
diminishing concentration. The absorption of DOX onto the
particles was further veriﬁed by performing confocal ﬂuorescence
microscopy (Fig. 3c and d). This technique allowed visualization
of the ﬂuorescence of DOX bound to the surface of the particles.
Our approach is general for all DNA-targeting chemotherapy
agents. To demonstrate this fact, we performed further experi-
ments on two additional common DNA-targeting chemother-
apeutics, cisplatin and EPI. We performed an initial cisplatin-
binding experiment in PBS solution with IONP-HN3-DNA and
monitored the decrease of cisplatin concentration by inductively
coupled plasma-mass spectrometry (ICP-MS). Approximately
20% of the cisplatin was captured from solution over 30 min, with
little improvement over longer time periods (see Supplementary
Fig. 4). We conﬁrmed the presence of captured cisplatin on the
surface of the particles by x-ray photoelectron spectroscopy. We
believe these relatively low levels of drug capture are due to
cisplatin not being in the aquo state, which happens intracellu-
larly and is necessary in order to bind to DNA. Because the
particles were not highly effective for cisplatin capture in PBS, we
did not perform further experiments in more complex media
such as serum or blood.
Along with DOX and cisplatin, EPI is among the most
commonly used chemotherapeutic agents for treating HCC. We
evaluated the efﬁcacy of our materials for capturing EPI using a
set of experiments analogous to those we used with DOX (see
Supplementary Fig. 5). Our particles were highly effective at
sequestering EPI from serum, with 68% captured after 25 min.
The sequestered amount would lead to a reduction in unwanted
side-effects if achieved in vivo.
In vitro evaluation of biological efﬁcacy. The ability of IONP-
HN3-DNA to detoxify DOX was tested in vitro in an H9C2 rat
heart myoblast cell culture assay (Fig. 4). These experiments
demonstrated that DNA-coated particles could rescue cultured
cardiac myoblasts from lethal levels of DOX more effectively than
the ion exchange resin Dowex, which itself had been previously
shown to reduce levels of DOX in vivo3.
In vivo evaluation of drug capture. A device (Fig. 5a) consisting
of IONP-HN3-DNA magnetically adhered to the surface of
cylindrical rare-earth magnets strung along a PTFE-coated nitinol
wire was evaluated using a closed loop ﬂow model3 (see Sup-
plementary Fig. 25) and subsequently tested in vivo using a
porcine model. The device was inserted into the IVC and DOX
was injected over 10 min at a rate of 2.5 mL/min into the left
common iliac vein proximal to the device (Fig. 5b). As the drug
ﬂowed through the IVC, it made contact with the IONP-HN3-
DNA adherent to the surface of the device and was captured.
Blood aliquots were taken proximal to (upstream), adjacent to the
midpoint of, and distal to (downstream from) the device
using separate catheters. Peak DOX concentration was
observed at 3 min, since the blood at the injection site
had recirculated and live injection was still underway. At 3
min (peak concentration), a 60% reduction in serum DOX
concentration was observed half-way across the device, while
a total reduction of 82% was observed at the end of the devi-
ce (Fig. 5c, d).
In conclusion, we have demonstrated two viable synthetic
pathways to genomic DNA-functionalized magnetic particles,
both on multi-gram scale. Moreover, these methodologies for
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DNA surface functionalization are not limited to magnetic metal
oxides, but may also be exploited for other substrates. The
synthesized materials captured three commonly used chemother-
apy agents from relevant biological solutions (PBS, human serum,
or porcine whole blood), at therapeutically relevant concentra-
tions and timescales. A proof of concept device was developed,
which demonstrated efﬁcient capture of DOX in vivo. Similar
devices could be readily developed that would potentially reduce
the off-target toxicity and damaging side-effects associated with
the use of DOX, cisplatin, and EPI during TACE or similar
procedures. Ultimately, we believe our approach is general for all
DNA-targeting chemotherapy drugs, and while further
development is needed, we hope that this work will provide a
foundation for future work on DNA-based materials and drug
capture approaches both for oncologic and non-oncologic
applications.
Methods
Instrumentation. Fluorescence measurements were made using a 96-well plate on
a Molecular Devices FlexStation 3 Multi-mode microplate reader. Scanning elec-
tron micrographs (SEM), as well as EDS measurements were made on a Zeiss
1550VP ﬁeld emission SEM equipped with an Oxford EDS module. ICP-MS was
carried out on an HP 4500 ICP-MS equipped with a Cetac ASX-500 autosampler.
Infrared measurements were made on a Nicolet iS50 Fourier transform infrared
spectrometer equipped with a DuraScope ATR unit. C, H, N analyses were carried
out using a PerkinElmer 2400 Series II CHN Elemental Analyzer. Fluorescence
microscopy was performed on an inverted laser scanning confocal Zeiss LSM 710
microscope equipped with an argon laser and photomultiplier tube detector, and
particle size was determined by image analysis of at least 100 particles measured on
their widest dimension.
General procedures. Unless otherwise stated reactions were carried out on the
bench. Fe3O4 (40 nm APS, 99%) was purchased from Nanostructured & Amor-
phous Materials, Inc. Silane reagents were purchased from Gelest, Inc. Genomic
DNA (isolated from Herring sperm), human serum (OptiClear), H9C2 rat heart
myoblasts, and cisplatin were purchased from Sigma Aldrich. DOX was purchased
from LC Labs and EPI was purchased from Biotang Inc. Potassium tetra-
chloroplatinate was purchased from Pressure Chemicals. All reagents not otherwise
mentioned were purchased from Sigma Aldrich, and were used without further
puriﬁcation.
Device construction. Twenty-ﬁve cylindrical rare-earth magnets (N52 grade,
5 mm OD × 1mm ID × 5mm L, magnetized through the diameter) were strung
along the length of a PTFE-coated nitinol wire (Terumo Glidewire). IONP-HN3-
DNA (1.0 g) was suspended in water and subsequently magnetically adhered to the
surface of this device.
Flow model experiments. A closed-circuit ﬂow model was used to measure DOX
clearance in a setting that simulates suprahepatic IVC conditions3,32. In this model,
the porcine blood is circulated through the polyvinyl chloride tubing at a rate
of ∼150 mL/min. The tubing size matches the average human hepatic vein mea-
suring 1.2 cm as described previously18. Testing was performed with 200 mL
porcine blood and samples were obtained from the tubing downstream from
the device.
In vitro experiments. H9C2 rat heart myoblasts (procured from Sigma Aldrich)
were cultured in well plates (four replicates per condition) for 48 h after which
cells were imaged with a light microscope and counted. In the control experiment,
cells were cultured in RPMI medium with 10% fetal bovine serum. In the DOX
experiment, cells were cultured with 0.05 mg/mL DOX added to the medium. In
the cell rescue experiments, 0.19 g of either Dowex ion-exchange resin or IONP-
HN3-DNA was added to the culture media prior to introduction of DOX (ﬁnal
DOX concentration: 0.05 mg/mL).
In vivo porcine experiments. In vivo device testing was performed in farm swine
(n= 1, 45–50 kg), which was under humane care. Experimentation was under
compliance with UCSF IACUC protocols. The animal was monitored with blood
pressure, pulse oximetry, heart rate, and electrocardiogram while under general
anesthesia with isoﬂurane. Using ﬂuoroscopic guidance, an 18Fr sheath was placed
into the left external iliac vein for introduction of the device. A pre-device sampling
catheter was introduced through the right external iliac vein with the tip termi-
nating in the left common iliac vein near the bifurcation. An additional catheter
was introduced via the right internal jugular vein with the tip distal to the device in
the IVC (post-device). The mid-device catheter and peripheral catheters were
introduced through the left internal jugular vein. Prior to the start of the experi-
ments, patency of the venous system was demonstrated using contrast injection
(Omnipaque). DOX was injected over 10 min at a rate of 2.5 mL/min into the left
common iliac vein proximal to the magnetic device. The pre-device DOX con-
centration was measured by sampling with a 5 Fr catheter downstream of the DOX
infusion. Blood aliquots were taken proximal to, adjacent to the midpoint of, and
distal to the device using separate catheters. To clear the sampling catheters, 2 mL
of blood was drawn immediately prior to taking the aliquot (3 mL). The blood
samples were placed on ice until they were centrifuged to isolate the plasma
fraction for analysis. A control experiment was also performed using the same
procedures but with no device inserted.
Particle synthesis. IONP-Pt: 3.31 g Fe3O4 was dried in vacuo at 120 °C. Upon
cooling, the sealed material was introduced into an inert atmosphere nitrogen
glovebox. To the Fe3O4 was added 23 mL anhydrous toluene along with 4 mL N-
(2-aminoethyl)-3-aminopropyltrimethoxysilane. The reaction was mechanically
stirred on the bench at 110 °C for 2 h and subsequently dried in vacuo at 110 °C for
20 h. The reaction mixture along with 1.0 g K2PtCl4, was stirred at 70 °C for 21 min
and then washed three times with water. Following this, the mixture was diluted to
a total volume of 450 mL with 18.2 MΩ water was treated with 1.3 g KCl and an
additional 10 mL water.
IONP-Pt-DNA: IONP-Pt materials along with 5.1 g deoxyribonucleic acid from
herring sperm were mechanically stirred in 450 mL 18.2 MΩ water at 37 °C for
20 h. To ensure covalent attachment as opposed to being physically adsorbed, the
particles were isolated from the reaction mixture, washed three times under
vigorous mechanical stirring with 18.2 MΩ water (400 mL) in order to remove
unbound DNA, frozen, and lyophilized to afford 3.08 g IONP-Pt-DNA (79% yield
based on elemental analysis of DNA content).
IONP-NH2: 4.2 g Of Fe3O4 was dried in vacuo at 120 °C. The Fe3O4 was
allowed to cool to room temperature under vacuum. To the Fe3O4 was added to
25 mL toluene (freshly dried over magnesium sulfate) and 3.2 mL 4-
aminobutyltriethoxysilane. The reaction was sealed and stirred mechanically for 2 h
at 120 °C. The reaction was removed from heat and the particles were isolated from
the toluene solution. The reaction mixture was washed once with toluene and
subsequently dried in vacuo at 120 °C for 1 h and 45 min. 4.02 g of IONP-HN3 was
isolated.
IONP-HN3-DNA: 3.4750 g IONP-HN3 was added to a vial along with 1.02 g
HN3·HCl and dimethylformamide (30 mL). The reaction was stirred mechanically
for 1 h at room temperature at which point, the particles were isolated from the
dimethylformamide. The particles were then washed three times with
dimethylformamide. The isolated particle as well as 3.35 g deoxyribonucleic acid
from herring sperm were transferred into a ﬂask along with 400 mL 18.2 MΩ water.
The reaction was mechanically stirred at 38 °C for 17 h and 45 min. To ensure
covalent attachment and to remove any unbound DNA, the particles were then
washed thoroughly under vigorous mechanical stirring three times with 18.2 MΩ
water (400 mL) and magnetic separation. The particles were then frozen in liquid
nitrogen and lyophilized to afford 3.79 g of IONP-HN3-DNA (89% yield as
calculated above).
Representative binding studies. DOX: To a scintillation vial was added 19 mL
human serum. Drug was injected at a concentration of 1 mg/mL from a con-
centrated stock, to bring the total concentration to ∼0.05 mg/mL. An initial time
point is taken before drug capture. DNA particles (100 ± 5mg) were added to the
serum mixture, which is constantly, mechanically stirred. 20 s before a time point is
taken, a strong, rare earth, magnet is used to isolate the particles at which point a
100 μL aliquot is taken and placed in a 96-well microplate. The solutions are then
measured by way of ﬂuorescence on a microplate reader.
Cisplatin: Phosphate-buffered saline solution (19 mL) was added to a
scintillation vial. Cisplatin solution (1 mL, 1 mg/mL solution) was then injected,
followed by 117 ± 5mg of IONP-HN3-DNA, and the mixture was mechanically
stirred over the course of an hour. At predetermined time points the magnetic
materials were temporarily isolated using an external magnet so that 100 μL
aliquots could be taken, which were diluted 200× in 2% nitric acid solution and
subsequently analyzed by ICP-MS to determine the concentration of platinum
remaining in solution.
EPI: Human serum (19 mL) was added to a scintillation vial. EPI solution in
water (1 mL, 1 mg/mL solution) was then added. The particles (100 ± 5mg IONP-
HN3-DNA) were then added and the solution was mechanically stirred over the
course of 25 min. At predetermined time points, the magnetic materials were
temporarily isolated using an external magnet and 100 μL aliquots were taken,
which were subsequently diluted 100× in water and analyzed by ﬂuorescence
on a microplate reader in order to characterize the amount of EPI remaining in
solution.
Data availability. All data supporting the ﬁndings of this study are available within
the article and its Supplementary Information. All other data are available from the
corresponding author upon reasonable request.
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